CAR-T therapies: Life-saving, yet unequally accessible.

A G20 health technology analysis

Ge et al., Blood (2026)

Global Access to CAR-T – *April 23rd*, 2026

Reimbursement is the basis for access

Less than half of CAR-T patients gain public access

18 FDA-approved CAR-T indications

14 countries with HTA* data

48% of drug-indication pairs are reimbursed

*HTA = Health Technological Assessment (reimbursement decisions)

Global Access to CAR-T – *April 23rd*, 2026 | Ge et al., Blood (2026)

Reimbursement recommendation

Percentage of the 18 FDA-approved CAR T-cell indications recommended for reimbursement, by country



USA = United States of America, GER = Germany, FR = France, CAN = Canada, JP = Japan, IT = Italy, ES = Spain, CH = Switzerland, GB-ENG = England, AU = Australia, GB-SCT = Scotland, SG = Singapore, SK = South Korea, BR = Brazil (CAR-T cells are not reimbursed or available in Brazil's public health system)

Global Access to CAR-T – *April 23rd*, 2026 | Ge et al., Blood (2026)

14 countries with HTA data

- 13 have at least 2 reimbursed CAR-T indication
- Brazil's public health system does not reimburse



Number of the 18 FDA-approved CAR T-cell indications recommended for reimbursement, by country

0 18

USA = 18, GER = 14, FR = 14, CAN = 12, JP = 11, IT = 10, ES = 9, CH = 9, GB-ENG = 7, AU = 7, GB-SCT = 5, SG = 4, SK = 2, BR = 0

Global Access to CAR-T – *April 23rd*, 2026 | Ge et al., Blood (2026)

easygen

Patients wait – but disease progression does not

Time is a critical barrier.

Why does it take so long from regulatory approval to HTA decision?

1.54
years average

6+
years in Switzerland

Global Access to CAR-T – *April 23rd*, 2026 | Ge et al., Blood (2026)

easygen

Why CAR-T evidence challenges HTA decisions

Single-arm trials

Small populations

Immature survival & QoL* data

High uncertainty in cost-effectiveness

HTA favors certainty – CAR-T delivers early uncertainty

*Quality of Life

Global Access to CAR-T – *April 23rd*, 2026 | Ge et al., Blood (2026)

One-time therapies don’t fit existing cost & payment models

- Very high upfront costs and added hospitalization costs
- Limited outcome-based payment
- Complex logistics

Global Access to CAR-T – *April 23rd*, 2026 | Ge et al., Blood (2026)

easygen

Access often fails early

No HTA submission

Withdrawn / incomplete dossiers

Delays despite positive decisions

easygen

How to improve access

Smarter payment models

Faster HTA & regulatory alignment

Decentralized treatment pathways

Global Access to CAR-T – *April 23rd*, 2026

easygen

EASYGEN (EU-funded IHI project)

Focuses on …

→ Cost-efficient manufacturing

→ Decentralized production models

→ Improved scalability

… to broaden patient access

Global innovation requires global access strategies – and projects like EASYGEN envision how Europe can move from breakthrough science to scalable patient access.

Global Access to CAR-T – *April 23rd*, 2026

The EASYGEN „EASY workflow integration for GENe therapy“ consortium (Grant ID: 101194710) is funded by the European Union, the private members, and those contributing partners of the IHI JU. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the aforementioned parties. Neither of the aforementioned parties can be held responsible for them.

easygen

COCIR Advancing Healthcare

efpia

EuropaBio The European Association for Bioindustries

MedTech Europe from diagnosis to cure

Vaccines Europe

Co-funded by the European Union